NOVO NORDISK is now bigger than Tesla. Due to Wegovy
Market valuation now US$566 Bn, number 12 in the world.
NOVO is conscious of the vulnerability of being exposed to a single therapeutic area.
The NOVO CEO said that the company is looking beyond diabetes and weight-loss treatment to include cardiovascular disease.
A portfolio manager commented that the cardiovascular field makes sense because it ties in with the clear cardiovascular benefits of Wegovy
Makes sense to me too. Potential partners must be conscious of Revascor. Competitively so
C'mon over NOVO. Get in first
Cell Therapy News/Articles, page-17494
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.040(3.54%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.09 | $10.61M | 9.616M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 241716 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.10 |
Change
-0.040 ( 3.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.09 | 1809171 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| MSB (ASX) Chart |